ESMO 2024 - A new medically promising antibody conjugate for metastatic breast cancer
Dr. Barbara Pistilli presents encouraging phase II ICARUS-BREAST01 results for patritumab deruxtecan, a new antibody-drug conjugate for metastatic breast cancer, showing a 53.5% response rate and 9.4 months median progression-free survival. The study identifies factors influencing response, suggesting potential as a new therapy for advanced hormone-dependent breast cancer.
Reference News
Dr. Barbara Pistilli presents encouraging phase II ICARUS-BREAST01 results for patritumab deruxtecan, a new antibody-drug conjugate for metastatic breast cancer, showing a 53.5% response rate and 9.4 months median progression-free survival. The study identifies factors influencing response, suggesting potential as a new therapy for advanced hormone-dependent breast cancer.